Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden

doi:10.3390/curroncol28060388

CNU IR > Pharmacy and Science > Dept. of Cosmetic Science and institute of cosmetic science > Periodical Articles > Item 310902800/34319

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34319

Title:	Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
Authors:	Kang, Nai-Wen Tan, Kien-Thiam Li, Chien-Feng Kuo, Yu-Hsuan
Contributors:	Chi Mei Med Ctr, Dept Internal Med, Div Hematol & Oncol ACT Genom Co Ltd Chi Mei Med Ctr, Dept Med Res Natl Inst Canc Res, Natl Hlth Res Inst Chia Nan Univ, Coll Pharm & Sci
Keywords:	neuroendocrine carcinoma immunotherapy immune checkpoint inhibitor tumor mutational burden
Date:	2021
Issue Date:	2023-11-11 11:43:05 (UTC+8)
Publisher:	MDPI
Abstract:	Poorly differentiated pancreatic neuroendocrine carcinomas (NECs) are rare and aggressive malignancies with rapid disease progression and early widespread metastasis. Given histology similarity, they are commonly treated with platinum-based chemotherapy as small cell lung cancer (SCLC). However, no standard treatment has been established for recurrent or progressive disease. We present an Asian patient with recurrent poorly differentiated pancreatic NEC after curative surgery and adjuvant chemotherapy with cisplatin and etoposide. The tumor mutational burden (TMB) was high. The patient received chemotherapy combined with maintenance immunotherapy with nivolumab and achieved promising and durable response, suggesting TMB could be a biomarker to identify NEC patients for immune checkpoint inhibitor (ICI) treatment.
Relation:	CURR ONCOL, v.28, n.6, pp.4587-4596
Appears in Collections:	[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

Files in This Item:

File	Description	Size	Format
curroncol28060388.pdf		3991Kb	Adobe PDF	88	View/Open
index.html		0Kb	HTML	251	View/Open

Loading...